An SMS Intervention to Improve Adherence to Stimulant Medications in Adults With ADHD
NCT ID: NCT04189536
Last Updated: 2022-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
125 participants
INTERVENTIONAL
2016-09-19
2022-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants in the study will receive customized text messages twice a day, every day, for a duration of 9 months. The text messages will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medication in Adults With ADHD in the Primary Care Setting
NCT04189575
A Text Messaging (SMS) Intervention to Improve Adherence to Stimulant Medications in Children With ADHD
NCT04189562
Text Messaging Adherence to Stimulant Medication
NCT01967485
Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder
NCT00429221
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
NCT03325881
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SMS Intervention
All subjects will receive customized text messages twice a day, every day for 9 months that will include reminders to adhere to the individualized medication regimen, reminders to call their clinician for a prescription refill followed by reminders to pick up medication from the pharmacy, and educational reminders about ADHD and its treatment.
SMS Intervention
Delivery of text messages will use the Rip Road Mobile platform.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SMS Intervention
Delivery of text messages will use the Rip Road Mobile platform.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM-V) Attention Deficit Hyperactivity Disorder based on clinical assessment
* Is starting stimulant medication or has begun treatment with stimulant medication within six months of study enrollment
* Proficient in English
* Has a cellular phone with text messaging capabilities and is interested in and willing to receive text messages
Exclusion Criteria
* Pregnant or nursing females
* Investigator and his/her immediate family
* Unwilling/unable to comply with study procedures
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph Biederman, MD
Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Biederman, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-P-001087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.